- $261.42bn
- $288.76bn
- $58.74bn
UK Stocks-Factors to watch on September 29 (updated)
AstraZeneca announces equity investment in Summit
HK's Akeso rallies after AstraZeneca invests $2 billion in Summit, backs ivonescimab
UK Stocks-Factors to watch on September 29
Brief: Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination (updated)
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit surges after AstraZeneca makes $2 billion equity investment
Brief: Astrazeneca Announces sBLA For Imfinzi Plus EV Granted Priority Review In US For MIBC
Live Markets: RBC says AI weakness appears to be fueling biotech rally
Brief: AstraZeneca PLC Announces Trixeo Approved In EU For Asthma
Trixeo approved in EU for asthma
European drugmakers call for faster trials, more spending to compete with US, China
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
Big Pharma growth malady has a risky cure
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up